ARIA
Library/regeneration/Thymosin Beta-4

Thymosin Beta-4

Not FDA Approved✓ WADA Permitted

Tβ4 / TB-4

regeneration◈Clinical EvidenceEndogenous actin-sequestering peptide

43-AA endogenous peptide in most tissues. Promotes cell migration, angiogenesis, wound healing, anti-inflammatory. Not WADA banned. Engineered versions showing promise in diabetic wound healing.

Confidence
55%
Half-Life ~hours
Cost ~$500/mo
Quick Reference
Routesubcutaneous
MechanismSequesters G-actin → actin polymerization → cell migration. VEGF, MMPs, laminin-...
SequenceSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Mol. Weight4921 Da
Reviewed2026-07-08

Mechanism of Action

Sequesters G-actin → actin polymerization → cell migration. VEGF, MMPs, laminin-5 upregulation. Stem cell differentiation. Cardio- and neuroprotective.

Dosing Protocol

Not standardized. Highly variable.

Key Studies

2025

Engineered Tβ4 corneal wound healing

PMID 41235866preclinical
2025

Tβ4-EVs diabetic wound healing

PMID 40279568preclinical
2023

Tβ4 bacterial keratitis adjunct

PMID 37018981preclinical

Adverse Effects

Limited human safety dataInjection site reactions

Contraindications

  • Active malignancy (theoretical)
  • Pregnancy

Storage

Lyophilized: frozen recommended. Reconstituted: refrigerate 2-8°C.

Clinical Applications

  • ["post_surgical_recovery"
  • "wound_healing"
  • "tissue_repair"]